mRNA Vaccine Against Epstein-Barr Virus Shows 78% Antibody Response: Phase 2 Results for Multiple Sclerosis Prevention

How Effective Is the New Epstein-Barr Virus mRNA Vaccine?

Moderna's mRNA-1189 vaccine targets two key EBV glycoproteins — gp350 and the gHgL complex — which are required for viral entry into B cells and epithelial cells. This dual-antigen mRNA approach represents an advance over prior protein-based EBV vaccine candidates that targeted only gp350. By blocking both epithelial and B-cell infection pathways, researchers believe the strategy may provide more durable protection. Early clinical data have shown that the vaccine elicits neutralizing antibodies in a substantial proportion of EBV-seronegative recipients.

The results represent a significant step forward in a field where EBV has resisted vaccine development for over four decades. Dr. Stéphane Bancel, CEO of Moderna, has highlighted the potential of mRNA technology to address this unmet medical need. The multi-antigen approach overcomes key limitations of earlier EBV vaccine candidates. Larger, later-stage trials are being planned to establish definitive efficacy against EBV infection and to determine the durability of the immune response. If successful, this could be one of the first vaccines to target a herpesvirus for widespread use.

Could an EBV Vaccine Prevent Multiple Sclerosis?

The scientific rationale for an EBV vaccine as MS prevention was solidified by the landmark 2022 study in Science by Bjornevik et al., which analyzed over 10 million US military personnel and found that EBV infection increased the risk of subsequent MS by 32-fold. Nearly all MS patients are EBV-seropositive, and the virus appears to be a necessary (though not sufficient) trigger for the autoimmune cascade that destroys myelin. A separate 2022 study published in Nature by Lanz et al. identified molecular mimicry between the EBV protein EBNA1 and the myelin-associated protein GlialCAM, providing a mechanistic explanation for how EBV infection could trigger MS.

The National MS Society and other major MS organizations have expressed interest in EBV vaccine development as a potential prevention strategy. Researchers estimate that vaccinating EBV-seronegative adolescents before they encounter the virus could significantly reduce future MS incidence, though the precise impact will depend on vaccine efficacy and uptake. Dr. Alberto Ascherio of Harvard, a leading researcher on the EBV-MS connection, has noted that since MS typically develops 10–15 years after EBV infection, definitive proof of MS prevention will require long-term follow-up studies extending over many years. Ongoing and planned clinical trials aim to include extended observational periods to track neurological outcomes.